安罗替尼在晚期恶性肿瘤治疗中的研究进展  

Research progress of anlotinib in the treatment of advanced malignant tumors

作　　者：崔广华 杨宇[1] CUI Guanghua;YANG Yu(Department of Medical Oncology,the Second Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属第二医院肿瘤内科,黑龙江哈尔滨150081

出　　处：《现代肿瘤医学》2022年第16期3032-3036,共5页Journal of Modern Oncology

基　　金：北京医卫健康公益基金会医学科学研究基金资助项目(编号:F2219A)。

摘　　要：安罗替尼是我国自主研发的多靶点小分子酪氨酸激酶抑制剂,具有抗肿瘤血管生成和抑制肿瘤细胞生长的作用,因其具有不良反应小、靶点明确及安全性高等优点,目前已在多种恶性肿瘤中显示出了良好的临床疗效,本文就安罗替尼的抗肿瘤作用机制、其在多种类型肿瘤中的应用以及不良反应与管理等方面的最新研究进展进行综合阐述。Anlotinib is a multi-target small molecular tyrosine kinase inhibitor independently developed in China,which has the effects of anti-tumor angiogenesis and inhibiting tumor cell growth.Because of its advantages such as small adverse reaction,clear target and high safety,it has shown good clinical efficacy in many kinds of malignant tumors.This article comprehensively reviews the anti-tumor mechanism of anlotinib,its application in many types of tumors,and the latest research progress in adverse reactions and management.

关 键 词：安罗替尼 酪氨酸激酶抑制剂 恶性肿瘤 抗肿瘤血管生成 

分 类 号：R730.5[医药卫生—肿瘤]